Indian Biotech Startup East Ocyon Bio Aims to Revolutionize the Cell & Gene Therapy Landscape
SciFocus/Dec 11, 2024 — East Ocyon Bio, a trailblazing startup in allogeneic Cell & Gene Therapy (CGT), has announced the successful closure of its $4.2 million seed funding round, led by Aeravti Ventures and Micro Labs. The funds will fuel pivotal initiatives, including preclinical testing, GMP manufacturing facility creation, and Phase I clinical trials, positioning East Ocyon Bio at the forefront of biotech innovation in India.
Key Highlights
- Funding and Leadership:
- $4.2 million seed round led by Aeravti Ventures and Micro Labs.
- Focus on bolstering India’s biotech ecosystem for global competitiveness.
- Dr Renu Kundu & Dr Dinesh Kundu, co-founders
- Core Initiatives:
- Preclinical testing of CAR-NK and CAR-gamma delta T cell therapies.
- Establishment of a state-of-the-art GMP manufacturing facility.
- Advancement to Phase I clinical trials for cutting-edge CGT solutions.
- Strategic Vision:
- Enable simultaneous local development and global launches of pioneering therapies.
- Enhance India’s role as a global hub for biotech innovation.
“This funding marks a significant milestone in our journey to transform India’s biotech landscape. By creating a robust ecosystem for Cell & Gene Therapy, we aim to deliver world-class solutions both locally and globally.”.
Why It Matters
- Accelerates the development of innovative therapies for cancer and other diseases.
- Establishes India as a competitive player in the global biotech arena.
- Addresses critical manufacturing and testing gaps in the CGT domain, fostering self-reliance.
This landmark funding sets the stage for East Ocyon Bio to revolutionize the biotech industry, pushing the boundaries of therapeutic innovation and positioning India as a leader in Cell & Gene Therapy advancements.
Website: https://www.eastocyonbio.com/
